Bioscience

ImmuneRegen initiates efficacy studies of anti-influenza drug

October 14, 2009

By Flinn Foundation

[Source: Trading Markets] – ImmuneRegen BioSciences, a wholly owned subsidiary of IR Biosciences Holdings, has reported that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 avian influenza in the laboratories of a university scientist.

The newly recognized H1N1-2009 influenza virus is also highly infectious, having spread throughout the world in a matter of months with a slightly higher lethality of 0.4% (mostly healthy younger individuals with no prior exposure, or therefore immunity, to this virus type). Early outbreaks of avian influenza (H5N1) in 2006, 2007 and 2008 were relatively contained but with very high lethality of 69%, 67% and 75%, respectively, said ImmuneRegen.

For more information: ImmuneRegen initiates efficacy studies of anti-influenza drug